162 related articles for article (PubMed ID: 35122394)
1. Antibodies gone bad - the molecular mechanism of light chain amyloidosis.
Absmeier RM; Rottenaicher GJ; Svilenov HL; Kazman P; Buchner J
FEBS J; 2023 Mar; 290(6):1398-1419. PubMed ID: 35122394
[TBL] [Abstract][Full Text] [Related]
2. Protease-sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation.
Mazzini G; Ricagno S; Caminito S; Rognoni P; Milani P; Nuvolone M; Basset M; Foli A; Russo R; Merlini G; Palladini G; Lavatelli F
FEBS J; 2022 Jan; 289(2):494-506. PubMed ID: 34482629
[TBL] [Abstract][Full Text] [Related]
3. Immunoglobulin light chain amyloid aggregation.
Blancas-Mejia LM; Misra P; Dick CJ; Cooper SA; Redhage KR; Bergman MR; Jordan TL; Maar K; Ramirez-Alvarado M
Chem Commun (Camb); 2018 Sep; 54(76):10664-10674. PubMed ID: 30087961
[TBL] [Abstract][Full Text] [Related]
4. Cell Damage in Light Chain Amyloidosis: FIBRIL INTERNALIZATION, TOXICITY AND CELL-MEDIATED SEEDING.
Marin-Argany M; Lin Y; Misra P; Williams A; Wall JS; Howell KG; Elsbernd LR; McClure M; Ramirez-Alvarado M
J Biol Chem; 2016 Sep; 291(38):19813-25. PubMed ID: 27462073
[TBL] [Abstract][Full Text] [Related]
5. Fatal amyloid formation in a patient's antibody light chain is caused by a single point mutation.
Kazman P; Vielberg MT; Pulido Cendales MD; Hunziger L; Weber B; Hegenbart U; Zacharias M; Köhler R; Schönland S; Groll M; Buchner J
Elife; 2020 Mar; 9():. PubMed ID: 32151314
[TBL] [Abstract][Full Text] [Related]
6. Light chain mutations contribute to defining the fibril morphology in systemic AL amyloidosis.
Karimi-Farsijani S; Pfeiffer PB; Banerjee S; Baur J; Kuhn L; Kupfer N; Hegenbart U; Schönland SO; Wiese S; Haupt C; Schmidt M; Fändrich M
Nat Commun; 2024 Jun; 15(1):5121. PubMed ID: 38879609
[TBL] [Abstract][Full Text] [Related]
7. Systemic Amyloidosis Due to Clonal Plasma Cell Diseases.
Bianchi G; Kumar S
Hematol Oncol Clin North Am; 2020 Dec; 34(6):1009-1026. PubMed ID: 33099420
[TBL] [Abstract][Full Text] [Related]
8. Amyloid formation in light chain amyloidosis.
Ramirez-Alvarado M
Curr Top Med Chem; 2012; 12(22):2523-33. PubMed ID: 23339305
[TBL] [Abstract][Full Text] [Related]
9. Amyloidogenic light chains impair plasma cell survival.
Pick M; Lebel E; Elgavish S; Benyamini H; Nevo Y; Hertz R; Bar-Tana J; Rognoni P; Merlini G; Gatt ME
Haematologica; 2023 Dec; 108(12):3359-3371. PubMed ID: 37381778
[TBL] [Abstract][Full Text] [Related]
10. Thermal stability threshold for amyloid formation in light chain amyloidosis.
Poshusta TL; Katoh N; Gertz MA; Dispenzieri A; Ramirez-Alvarado M
Int J Mol Sci; 2013 Nov; 14(11):22604-17. PubMed ID: 24248061
[TBL] [Abstract][Full Text] [Related]
11. Mutations in specific structural regions of immunoglobulin light chains are associated with free light chain levels in patients with AL amyloidosis.
Poshusta TL; Sikkink LA; Leung N; Clark RJ; Dispenzieri A; Ramirez-Alvarado M
PLoS One; 2009; 4(4):e5169. PubMed ID: 19365555
[TBL] [Abstract][Full Text] [Related]
12. Driving forces in amyloidosis: How does a light chain make a heavy heart?
Otzen DE
J Biol Chem; 2021; 296():100785. PubMed ID: 34019874
[TBL] [Abstract][Full Text] [Related]
13. The Process of Amyloid Formation due to Monoclonal Immunoglobulins.
Morgan GJ; Wall JS
Hematol Oncol Clin North Am; 2020 Dec; 34(6):1041-1054. PubMed ID: 33099422
[TBL] [Abstract][Full Text] [Related]
14. Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wide copy number array analysis.
Granzow M; Hegenbart U; Hinderhofer K; Hose D; Seckinger A; Bochtler T; Hemminki K; Goldschmidt H; Schönland SO; Jauch A
Haematologica; 2017 Jul; 102(7):1281-1290. PubMed ID: 28341732
[TBL] [Abstract][Full Text] [Related]
15. Comparison of IGLV2-14 light chain sequences of patients with AL amyloidosis or multiple myeloma.
Berghaus N; Schreiner S; Poos AM; Raab MS; Goldschmidt H; Mai EK; Salwender HJ; Bernhard H; Thurner L; Müller-Tidow C; Weinhold N; Hegenbart U; Schönland SO; Huhn S
FEBS J; 2023 Sep; 290(17):4256-4267. PubMed ID: 37097223
[TBL] [Abstract][Full Text] [Related]
16. A constant domain mutation in a patient-derived antibody light chain reveals principles of AL amyloidosis.
Rottenaicher GJ; Absmeier RM; Meier L; Zacharias M; Buchner J
Commun Biol; 2023 Feb; 6(1):209. PubMed ID: 36823438
[TBL] [Abstract][Full Text] [Related]
17. Systemic amyloidoses.
Blancas-Mejía LM; Ramirez-Alvarado M
Annu Rev Biochem; 2013; 82():745-74. PubMed ID: 23451869
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis and management of systemic light chain AL amyloidosis.
Bhutani D; Lentzsch S
Pharmacol Ther; 2020 Oct; 214():107612. PubMed ID: 32562825
[TBL] [Abstract][Full Text] [Related]
19. Inherent Biophysical Properties Modulate the Toxicity of Soluble Amyloidogenic Light Chains.
Maritan M; Romeo M; Oberti L; Sormanni P; Tasaki M; Russo R; Ambrosetti A; Motta P; Rognoni P; Mazzini G; Barbiroli A; Palladini G; Vendruscolo M; Diomede L; Bolognesi M; Merlini G; Lavatelli F; Ricagno S
J Mol Biol; 2020 Feb; 432(4):845-860. PubMed ID: 31874151
[TBL] [Abstract][Full Text] [Related]
20. The Ultrastructure of Tissue Damage by Amyloid Fibrils.
Koike H; Katsuno M
Molecules; 2021 Jul; 26(15):. PubMed ID: 34361762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]